3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
52
Hodgkin Disease
29
Lymphoma
15
Sarcoma
7
Neoplasm Metastasis
7
Uveal Melanoma
6
Skin Neoplasms
6
Neoplasms
5
Leiomyosarcoma
5
Solitary Fibrous Tumors
2
Sarcoma, Synovial
2
Neuroblastoma
2
Hematologic Diseases
2
HIV Infections
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Melanoma Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lung Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
Dacarbazine
×
Clear all
NCT00070642
2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2
Completed
184 enrolled